Difference between revisions of "Team:Northeastern Boston"

Line 218: Line 218:
 
<p><i>"Dr. George D. Yancopoulos, chief scientific officer of Regeneron, said the crisis had pointed up shortcomings in biodefense. “Nobody is really prepared,” he said. “Nobody in the world has rapid response capabilities.”</i>—New York Times, January 2015</p>
 
<p><i>"Dr. George D. Yancopoulos, chief scientific officer of Regeneron, said the crisis had pointed up shortcomings in biodefense. “Nobody is really prepared,” he said. “Nobody in the world has rapid response capabilities.”</i>—New York Times, January 2015</p>
  
−
    <p id="project_description__p__one">Northeastern is working to standardize protein production in microalgae. <i>Chalmydomonas reinhardtii</i>, the workhorse of algae research, is an attractive chassis for several reasons. Its primary carbon source is CO<sub>2</sub>, it rapidly divides, and it’s a capable of complex post-translational modifications.</p>
+
    <p id="project_description__p__one">Northeastern is working to standardize protein production in microalgae. <i>Chlamydomonas reinhardtii</i>, the workhorse of algae research, is an attractive chassis for several reasons. Its primary carbon source is CO<sub>2</sub>, it rapidly divides, and it’s a capable of complex post-translational modifications.</p>
  
 
<p>Microalgae are relatively inexpensive to scale, yet have all the production capabilities of other Eukaryotic organisms (di-sulfide bonds and glycosylation). This capability could be exploited to treat human disease. For example, there was a shortage of an “antibody-cocktail” during the Ebola outbreak.</p>
 
<p>Microalgae are relatively inexpensive to scale, yet have all the production capabilities of other Eukaryotic organisms (di-sulfide bonds and glycosylation). This capability could be exploited to treat human disease. For example, there was a shortage of an “antibody-cocktail” during the Ebola outbreak.</p>

Revision as of 10:59, 17 September 2015

NORTHEASTERN

"Dr. George D. Yancopoulos, chief scientific officer of Regeneron, said the crisis had pointed up shortcomings in biodefense. “Nobody is really prepared,” he said. “Nobody in the world has rapid response capabilities.”—New York Times, January 2015

Northeastern is working to standardize protein production in microalgae. Chlamydomonas reinhardtii, the workhorse of algae research, is an attractive chassis for several reasons. Its primary carbon source is CO2, it rapidly divides, and it’s a capable of complex post-translational modifications.

Microalgae are relatively inexpensive to scale, yet have all the production capabilities of other Eukaryotic organisms (di-sulfide bonds and glycosylation). This capability could be exploited to treat human disease. For example, there was a shortage of an “antibody-cocktail” during the Ebola outbreak.